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Cervical cancer (CC) mortality is a major public health concern since it is the second cause of cancer-related deaths
amongwomen. Patients diagnosedwith locally advanced CC (LACC) have an important rate of recurrence and treatment
failure.Conventional treatment for LACC isbasedonchemotherapy and radiotherapy; however, up to40%ofpatientswill
not respond to conventional treatment; hence,we searched for a prognostic gene signature able to discriminate patients
who do not respond to the conventional treatment employed to treat LACC. Tumor biopsies were profiled with genome-
wide high-density expression microarrays. Class prediction was performed in tumor tissues and the resultant gene
signaturewas validated by quantitative reverse transcription–polymerase chain reaction. A 27-predictive gene profilewas
identified through its association with pathologic response. The 27-gene profile was validated in an independent set ofdid histopathologic analysis. J.F.-R. and F.L.-G. carried out the processing of
microarrays, acquisition of data and analysis, and interpretation of data. J.F.-R., F.L.-G., E.L.-U.,
andC.P.-P. planned anddraw all figures anddiscussed themanuscript. J.F.-R., F.L.-G.,N.J.-H.,
N.R.-N., and C.P.-P. wrote and revised the manuscript.
4This article refers to supplementary materials, which are designated by Supplementary
Tables S1 and S2 and Supplementary Figures S1 to S3 and are available online at
www.transonc.com.
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78 Transcript Profiling Fernandez-Retana et al. Translational Oncology Vol. 8, No. 2, 2015patients and was able to distinguish between patients diagnosed as no response versus complete response. Gene
expression analysis revealed two distinct groups of tumors diagnosed as LACC. Our findings could provide a strategy to
select patients who would benefit from neoadjuvant radiochemotherapy-based treatment.
Translational Oncology (2015) 8, 77–84Table 1. Clinical-Pathologic Status of CCLA Patients (n = 119)
Characteristics Patients
N Percentage
Age
Median 48
Range 29-69
Histologic type
Squamous cell carcinoma 109 92.59%
Adenocarcinoma 10 8.41%
Tumor size
≤4 cm 41 34.45%
≥4 cm 71 59.66%
Without data 7 5.88%
Clinical stage (FIGO)
IB2 14 11.76%
IIA 1 0.84%
IIB 76 63.86%
IIIA 1 0.84%
IIIB 27 22.68%
HPV genotyping (frequency)
Type 16 57 37.74%
Type 18 28 18.54%
Type 45 16 10.59%
Type 33 8 6.72%
Others 33 21.85%
Not determined 9 5.96%
Patients with HPV co-infection 33 27.73%
Patients without HPV co-infection 77 64.70%
Not determined 9 7.56
Treatment outcome
CR 79 66.38%
NR 36 30.25%
Without date for desertion 4 3.36%
All patients received radiotherapy and cisplatin as coadjuvant (50-Gy external radiation, 35-Gy
intracavitary brachytherapy, and six cycles of 40 mg/m2cis-diamminedichloroplatinum(II)).Introduction
Cervical cancer (CC) is the second leading cause of cancer-related
deaths among women worldwide with an estimated 275,000 deaths
in 2008; about 88% of them occur in developing countries. More
than 80% of patients affected by CC have large tumors of advanced
stage mainly those classified as locally advanced cervical cancer
(LACC), for whom the mortality/incidence ratio is about 50% [1,2].
As with other cancers, treatment depends mainly on progression stage
and some clinical characteristics such as tumor size [3,4]. LACC is defined
by tumors confined to the pelvic wall; therefore, those patients have no
distant metastasis. The standard treatment for patients diagnosed with
LACC with International Federation of Gynecology and Obstetrics
(FIGO) stages from IB2 to IVA [5] consists of radiotherapy in
combination with cisplatin-based chemotherapy (40 mg/m2) followed
by brachytherapy [5,6]; regrettably, the number of deceased patients due
to disease progression after 5 years is as high at 50% [1].
Concomitant treatment based on chemotherapy and radiotherapy
(CRT) has provided clinical benefits for pelvic control of CC;
however, it has important toxicity in several patients, and some
studies have shown that it could not significantly extend the overall
survival in at least 40% of patients [7,8]; in addition, up to 35% of
patients experience disease progression after CRT [9]. This scenario
highlights the need for early detection of innate resistance to
conventional or standard therapy, which would allow physicians to
provide tailored treatment alternatives as early as possible. The advent
of high-throughput technologies enables us to define patients’ tumors
as a function of their gene expression profile and use this information
to improve identification of patients that would benefit with
conventional treatment and those in need of adjuvant therapy.
Such an approach has been developed for breast cancer [10], leukemia
[11], colon cancer [12], and B cell lymphoma [13]. Nevertheless, this
approach is only currently applied in the clinic to breast cancer in the
form of MammaPrint (www.agendia.com) and to prostate and colon
cancers through Oncotype DX [14] (www.oncotypedx.com).
Patients who do not respond to conventional treatment could
require other chemotherapy-based treatment schemes; therefore, their
timely detection is crucial. To contribute to this aim, we searched for
a gene expression signature able to predict the clinical outcome for
LACC patients who receive conventional treatment as soon as at the
time of diagnosis.
Thus far, there are no reports showing the use of microarrays to
identify gene signatures associated with clinical response to CRT in
LACC; here, by means of transcriptome profiling and machine
learning algorithm, we identified a group of genes that can be used as
molecular markers to predict the clinical outcome in those patients.
Our rationale is that primary tumors that have not received any
conventional treatment (virgin to treatment) carry expression patterns
capable of predicting the potential tumor progression; hence, accurate
identification of genes involved in the innate resistance could beemployed as a prognosis signature associated with CRT treatment–
derived clinical response. In this study, we analyzed the genome-wide
expression profiles in a discovery group consisting of 89 LACC
patients receiving conventional or standard treatment (CRT) by
means of genome-wide high-density arrays, covering 45,000
expressed sequences. A nearest-mean classifier was trained for probe
selection in a leave-one-out cross-validation process. We obtained a
27-gene signature capable of predicting with high significance the
clinical response as complete response (CR) versus no response (NR).
Next, gene expression values were confirmed by quantitative reverse
transcription–polymerase chain reaction (qRT-PCR) on an inde-
pendent validation group of 30 patients, confirming the gene
expression signature.
Material and Methods
Tumor Samples
The population under this study included 119 patients prospec-
tively enrolled into the National Cancer Institute of Mexico
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2010 through August 2012). All patients included accept and signed
informed consent; institutional ethics and scientific board committees
approved the protocol. Immediately after punch biopsy, tumor
samples were split into three pieces, one for pathologic confirmation
of at least 80% of tumor cells that is mandatory for this type of
molecular profiles and the remaining two for RNA and DNA
isolation. RNA and DNA biopsies were frozen in liquid nitrogen until
nucleic acid extraction. Eligibility criteria were 1) patients with a
confirmed pathologic diagnosis of CC staged IB2 up to IIIB (LACC);
2) biopsies with pathology report with more than 80% of tumors
cells; hence, the genomic analysis is mainly addressed for tumor cells;
3) age greater to 20 and less than 60 years; 4) high-quality DNA and
RNA; 5) no presence of comorbidities; 6) without previous oncological
treatment; and 7) patients able to receive standard or conventional
therapy based on concurrent CRT. Chemotherapy was based on weekly
cis-diamminedichloroplatinum(II) at 40 mg/m2 during five to six cycles.
Radiotherapy consisted of external radiation and intracavitary brachy-
therapy, for a total dose of 64 to 66 Gy over 67 days [6]. Hence, all
patients received the same conventional treatment. Clinical characteristics
of patients are summarized in Table 1.
Clinical Definitions
Staging was assessed according to the FIGO classification [15]. Clinical
responses were evaluated by RECIST 1.1 criteria and computed axial
tomography scan and were assigned as CR, defined as the disappearance
of all signs of cancer in response to treatment, andNR, defined as patients
with partial, progressive, or stable disease [16].
HPV Genotyping
DNA was obtained from cervical tumor biopsies by means of
MagNAPure Compact Instrument following the manufacturer's
recommendations (Roche Diagnostics GmbH, Roche Applied
Science, Mannheim, Germany). HPV genotyping was assessed by
two approaches, linear array HPV genotyping (Roche Diagnostics
GmbH, Roche Molecular Biochemicals, Mannheim Germany) and
nested multiplex PCR (MY/GP primers) with subsequent PCR-frag-
ment direct sequencing [17].
RNA Purification and Microarray Hybridization
Eighty-nine samples obtained at the time of diagnoses were used to
discover a gene expression signature associated with clinical response.
We compared gene expression signatures from patients with CR
against patients diagnosed as NR. The quality of RNA was assessed by
means of 18S:28S ratio. Hybridization targets were prepared from
250 ng of total RNA and amplified with whole transcriptome
amplification kit 2 (Sigma-Aldrich, St Louis, MO). Four micrograms
of amplified and Cy3-labeled cDNA was used to hybridize onto
high-density arrays containing 45,000 features according to the
recommended protocol of Nimblegen Roche (Mannheim, Germany).
After standard washes, arrays were scanned on the Nimblegen MS200
microarray scanner. Images were stored for further analyses.Microarray Preprocessing and Statistical Analysis
Scanned images were gridded by using the NimbleScan v2.6
Software (Nimblegen Roche). Then, robust multi-array analysis
background normalization and quantile normalization were per-
formed for intra-array and inter-array normalization, respectively.
Genes with signal intensities above a 95% random threshold werechosen [18]. Differential expression between clinical outcomes was
assessed by moderated t tests and significance statistics for each gene
were obtained by the empirical Bayes method implemented in limma
package from Bioconductor [19]. Global differential expression was
also examined by random sampling of class labels. We selected gene
subsets on the basis of classifier optimal performance ranking, as in
previous approaches [20,21]. A nearest mean classifier was trained for
feature selection in a leave-one-out cross-validation process and
feature selection was further tested by another leave-one-out
cross-validation procedure to select the profile with the strongest
association with clinical response. Graphics were generated using
Genesis 2.1 software [22]. The total microarray raw and normalized
data of this study are public available at the Gene Expression
Omnibus database (http://www.ncbi.nlm.nih.gov/geo/) with acces-
sion number GSE56303.
Validation of Gene Expression Profile by qRT-PCR
We employed the remaining 30 samples to validate the gene
expression profile identified in the discovery tumor set. Twenty-seven
differentially expressed genes were subjected to qRT-PCR. Each
primer set was designed by an experimentally verified computer
algorithm and then tested in a quality control assay to guarantee that
they yield a single band of the predicted size by agarose gel
electrophoresis. The sequence of primers and PCR conditions are
shown in Supplemental Table S1. RT reactions were performed
according to the MMLV protocol from Promega (Madison, WI)
following the vendor's recommendations. Real-time PCR was
performed using FastStart SYBR Green Master in Light Cycler 480
Instrument II (Roche, Mannheim, Germany) according to the
manufacturer's protocol. Duplicate RT samples were used in each
assay, data were normalized with β-actin housekeeping gene, and in a
parallel way, glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was
used. The comparative Ct method (ΔΔCt) was used to quantify gene
expression, and relative quantification was calculated as 2−ΔΔCt for
both housekeeping genes.
Disease-Free Survival
Disease-free survival (DFS) of the resulting patient groups was
evaluated using the Kaplan-Meier method, and the statistical
significance of survival differences was determined with the log-rank
test. Multivariate analysis for confounding factors was performed with
the Fisher exact test.
Results
Patient Characteristics
Relevant clinical information of 119 recruited patients in this study is
shown in Table 1. The median age at diagnosis was 48 years (range 29 to
59 years). The majority of patients were diagnosed as IIB (63.8%) and
IIIB stages (22.7%); 92.6% were squamous cell carcinomas, while 8.4%
were adenocarcinoma histologic type. The main HPV types were 18
(18.5%) and 16 (37.7%); an important number of patients (27.7%)were
infected with two or moreHPV types. Themedian clinical follow-up was
24 months. Thirty-six (30.2%) patients had NR, while seventy-nine
(66.4%) were diagnosed as complete responders (CR), and four patients
(3.3%) withdrew from the protocol.
Gene Expression Profile from 89 Tumors
To identify genes differentially expressed in pretreatment biopsies of
responders (CR) and non-responders (NR), we applied a supervised
Figure 1. Supervised two-dimensional cluster analysis of 89 CC tumor profiles. Two-dimensional presentation of transcript ratios for 89
CC tumors. We selected 2133 genes with fold change N1.5 and P value b .02. In the right panel, each individual’s response diagnosis
status after 2.5-year follow-up period is indicated as black squares for NR and white squares for CR. Clinical characteristics such as stage
(FIGO classification), tumor size N4 cm, and co-infection by two of more HPV types are shown as gray squares.
Table 3. Multivariate Significance Analysis
Clinical Feature CR NR P Value
Multivariate analysis of cluster A with CR and NR (n = 56)
FIGO stage IB2/IIA/IIB 35 7 P = .664 Not significantly
80 Transcript Profiling Fernandez-Retana et al. Translational Oncology Vol. 8, No. 2, 2015classification based on moderated t tests and significance statistics
obtained by the empirical Bayesmethod.We obtained a list of 2133 genes
with significant differential expression (P b .02). Figure 1 shows a
two-dimensional hierarchical clustering using Pearson correlation
distance and complete linkage clustering obtained from Genesis 2.1
software [22]. Dendrograms shown in Figure 1 represent the similarity
between clinical samples based on gene expression profiles; the length and
subdivision of the branches show the similarity between CC tumors (left)
and the gene expression profiles (top). The four patients who withdrew
from the protocol are represented in red in the left dendrogram. Two
tumor groups are clearly observed; the dashed line indicates the
subdivision of these two main groups. In the top group (cluster A),
there are 56 tumor samples, from which 46 responded favorably (CR
group), which represents 82.1% of tumors contained in cluster A. While
the bottom group (cluster B) contains 33 samples, from which 14
(42.4%) had no response (NR group), this feature suggests that LACC
tumors can be divided with respect to their clinical outcome based on the
differential expression pattern of 2133 genes (fold change N1.5 and P b
.02). Information explaining clinical outcome and the relationship
between both clusters to some relevant clinical features is shown in
Table 2. To have a complete clinical perspective, we associated tumorTable 2. Clinical Features Associated with Supervised Two-Dimensional Cluster Analysis of 89 CC
Tumor Profiles
N Patients Who
Withdrew
CR NR IB2 IIA IIB IIIA IIIB Tumor
Size ≥ 4
HPV
Co-Infection
Cluster A 56 2 46 8 5 1 36 1 13 29 11
Cluster B 33 2 17 14 5 0 21 0 7 25 12
Overall 89 4 63 22 10 1 57 1 20 54 23gene expression profiles with informative clinical features: FIGO stage,
tumor size, and co-infections by two or more HPV types. Of 68 tumors
classified as IB2 to IIB stages, 42 were grouped in cluster A and 26 in
cluster B; from21 tumors classified IIIA to IIIB, 14 and 7were grouped in
clusters A and B, respectively. Tumor size is a clinical marker frequently
used as a clinical response predictor [3,4]; from 54 biopsies with an initial
tumor size greater than four centimeters, 29 (53.7%) belonged to cluster
A and 25 (46.2%) were grouped in cluster B. Regarding HPV
co-infection, of 23 samples with two or more HPV types, cluster A had
11 samples and the rest were grouped in cluster B; therefore, tumor
samples with HPV co-infection grouped in cluster B represent 36.3% of
the samples. The multivariate significance analysis of clinicalIIIA/IIIB 13 1
Tumor size b4 cm 26 1 P = .052 Not significantly
≥4 cm 22 7
HPV infection Single 40 5 P = .181 Not significantly
Co-infection 8 3
Multivariate analysis of cluster B with CR and NR (n = 33)
FIGO stage IB2/IIA/IIB 18 8 P = 0.026 Significantly
IIIA/IIIB 1 6
Tumor size b4 cm 7 1 P ≤ .098 Not significantly
≥4 cm 12 13
HPV infection Single 12 9 P = 1.000 Not significantly
Co-infection 7 5
P Values for stage, tumor size, and HPV co-infection were calculated by Fisher exact test.
Figure 2. CC-CTRP. The predictor genes are clustered based on their similarities across the 89 tumors. The left panel shows tumors
ordered according to their CC-CTRP score; the red line divides positive and negative values. White circles indicate CR tumors, and black
circles indicate NR cases. The heat map (right) shows the expression of the 27-gene signature.
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Figure 3. Kaplan-Meier DFS analysis based on 27-gene predictor
stratification. The behavior of CC-CTRP for patients with NR to
conventional treatment is shown by a dotted line and that for
patients with CR is shown by a continuous line; both groups are
clearly separated within the first months. Clinical response was
assessed according to RECIST 1.1 criteria.
82 Transcript Profiling Fernandez-Retana et al. Translational Oncology Vol. 8, No. 2, 2015characteristics summarized in Table 3 showed that only FIGO stage had a
slight significant association to clinical response (P = .026).
Prediction Model for the Prognostic Profile in LACC
To identify genes with scores capable of discriminating between
CR and NR clinical outcomes, we employed a supervised
classification approach that has shown success in previous studies
[20,21]. Genes ranked by significance of differential expression were
used and a nearest mean classifier was trained in a leave-one-out
cross-validation process to select genes with the best classifier
performance. Using the predictive algorithm, a 27-gene signature
was developed with maximum accuracy in predicting clinical response
status (sensitivity: 74%, that is the capacity to predict patients with
NR; specificity: 91.3%, that predict the patients with CR; and overall
accuracy of 90%); Figure Supplementary S1 shows the classifier
performance, while the description of the 27-gene signature is
summarized in Supplementary Table S2. The expression pattern of
genes present in this 27-gene signature panel is shown in Figure 2.
The left panel shows the classifier itself, clinical outcome is
represented with black circles for patients with NR and white circles
for CR, and the score for each one is indicated in the x-axis.
According to this score, patients were divided in two groups delimited
by a red line: 17 of 21 (80%) patients with NR and 62 of 68 (91%)
patients with CR were assigned the expected score (lying to the right
and left of the red line, respectively) showing the high sensitivity and
specificity of our predictor. Each patient’s 27-gene profile is displayed
in the heat map at the right, where contrasting patterns can be
observed at the top and bottom, suggesting an expression profile
gradient between patients with the best (top) and worst (bottom)
prognoses. Interestingly, the apparent threshold indicated by a
horizontal black line corresponds to the actual disease outcome of
the patients represented by black or white circles in the classifier at
the left. Moreover, Kaplan-Meier analysis showed a statistically
significant difference in DFS between the NR and CR groups
(Figure 3). The NR group had a mean DFS of 16 months, whereas
the CR had a median survival that had not yet been reached
(log-rank P = 1 × 10−16).
Validation by qRT-PCR
To confirm the discrimination capability of the Cervical Cancer
Conventional Treatment Response Profile (CC-CTRP) gene signa-ture, we searched for gene expression levels of all 27 genes that were
validated by qRT-PCR in an independent group formed by 30
independent patients with LACC diagnosis. Total RNA was isolated
from biopsies taken before treatment; diagnosis-wise 16 of these
patients were classified as CR and 14 as NR. For the sake of clarity, we
analyzed the qRT-PCR results as ΔΔCt(log2), which represents the
fold change relative to the β-actin housekeeping gene (Figure 4A); in a
parallel analysis, we used another housekeeping gene (GAPDH) to
confirm the consistency of results (Figure 4B). Although GAPDH
and β-actin housekeeping genes showed slight differences in
expression levels (Supplementary Figure S2), the ability to discrim-
inate both clinical responses (CR vs NR) does not show significant
differences (Supplementary Figure S3, A and B). Hence, the
RT-PCR results were evaluated as ΔΔCt(log2) grouped patients in
accordance with the initial 27-gene classifier, regardless of the source
of the data, qRT-PCR, or microarrays.
Discussion
Despite of the increase in early detection programs, CC still remains
one of the principal neoplasms causing death of women throughout
the world since most patients are diagnosed only when they arrive to
health centers and the disease has often reached locally advanced
stages. Thus far, no generally accepted molecular marker for CC has
been reported [23] and clinical parameters are the only strategy
currently used in the prediction of disease outcome.
In this work, we aimed to find a molecular signature associated
with chemo-radioresistance of LACC; tumor biopsies were carefully
selected to fulfill inclusion criteria, which included that each biopsy
had more than 80% of tumor cells. We obtained the differentially
expressed gene profiles and their correlation with the clinical outcome
of 89 tumors and used these data to build a predictor algorithm to
identify chemoradiotherapy-resistant individuals. The data were later
validated by assessing 30 additional samples in an independent group,
for a total of 119 LACC analyzed patients.
We identified a 27-gene molecular signature with high prognostic
value, which proved to be more effective than tumor size in predicting
disease outcome that is currently the main clinical approach used as
predictive marker [3] (Table 3). Our predictor sorted correctly 17 of
22 patient diagnoses; this figure represents 80% of effectiveness. The
Kaplan-Meier graph in Figure 3 shows that disease outcome can be
identified as early as 4 months by using our approach.
Several works have used microarray technologies in the search for
CC molecular signatures associated with different conditions such as
radioresistance [24–26], early stage lymph node metastasis [27], and
resistance to angiocidin and darapladib-based anti-tumoral and
anti-inflammatory treatment [28]. However, despite assessing the
same tumor type, these molecular signatures lack consistency, mainly
because treatment selection is not based on NCI standards, which
could affect the reported genes. In addition, this may result from the
diverseness of the experimental designs or intrinsic bias of the
different microarray platforms [23]. However, the populations that
these authors have analyzed, while seemingly similar, are actually very
diverging when observed from the perspective of the therapy. Thus,
we find it reasonable to speculate that different treatments elicit
variable but specific gene expression profiles. Moreover, intra-tumor
source heterogeneity is an important but seldom considered point.
Bachtiary and co-workers suggest that increasing sample size can serve
as a remedial measure, based on variance-component analysis of the
genetic properties of replicate cancer biopsies [29]. Currently, there is
Figure 4. qRT-PCR validation. The cluster illustrates a comparison of data from real-time qRT-PCR of 30 patient analyses of each of the
CC-CTRP signature. Clustering was obtained by means of their similarities (Pearson correlation and complete linkage clustering). Black
squares represent non-responders; white squares represent complete responders. Gene expression levels were normalized to (A) β-actin
and (B) GAPDH.
Translational Oncology Vol. 8, No. 2, 2015 Transcript Profiling Fernandez-Retana et al. 83no previous report of a molecular signature associated with
conventional treatment response. To our knowledge, this work is
the first transcriptome-based molecular signature associated with
conventional treatment based on chemoradiotherapy resistance and
the largest LACC sample number assessed in such a study.Conclusion
Patients diagnosed with LACC are submitted to conventional
treatment, without certainty of a CR, due to tumor chemo-
radiotherapy resistance. The CC-CTRP gene signature, obtained in
this work, is a novel prognosis tool aimed at sorting patients with
regard to their sensibility to conventional treatment; consequently, it
would be possible to give those with a bad prognosis the opportunityto undertake alternative or complementary treatment without prior
exposition to conventional treatment, avoiding unnecessary weaken-
ing and thus increasing their survival possibilities. However, more
studies would be necessary to increase evidence about the utility of the
current molecular signature.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.tranon.2015.01.003.
Acknowledgements
This manuscript was submitted in partial fulfillment of J.F.-R.'s
requirements for a PhD degree in Posgrado en Ciencias Biologicas,
UniversidadNacional Autonoma deMexico.Wewant to acknowledge the
technical support of Abraham Pedroza for housekeeping gene experiments.
84 Transcript Profiling Fernandez-Retana et al. Translational Oncology Vol. 8, No. 2, 2015References
[1] Green JA, Kirwan JM, Tierney JF, Symonds P, Fresco L, and Collingwood M, et al
(2001). Survival and recurrence after concomitant chemotherapy and radiotherapy for
cancer of the uterine cervix: a systematic review and meta-analysis. Lancet 358,
781–786. http://dx.doi.org/10.1016/S0140-6736(01)05965-7.
[2] Jemal A, Bray F, CenterMM, Ferlay J,Ward E, and FormanD (2011). Global cancer
statistics. CA Cancer J Clin 61, 69–90. http://dx.doi.org/10.3322/caac.20107.
[3] Kapp KS, Poschauko J, Tauss J, Berghold A, Oechs A, and Lahousen M, et al
(2005). Analysis of the prognostic impact of tumor embolization before definitive
radiotherapy for cervical carcinoma. Int J Radiat Oncol Biol Phys 62, 1399–1404.
http://dx.doi.org/10.1016/j.ijrobp.2004.12.037.
[4] KappKS, StuecklschweigerGF, KappDS, Poschauko J, PickelH, and LahousenM,
et al (1998). Prognostic factors in patients with carcinoma of the uterine cervix
treated with external beam irradiation and IR-192 high-dose-rate brachytherapy. Int
J Radiat Oncol Biol Phys 42, 531–540.
[5] Waggoner SE (2003). Cervical cancer. Lancet 361, 2217–2225.
http://dx.doi.org/10.1016/S0140-6736(03)13778-6.
[6] National Comprehensive Cancer Network (NCCN) (2009). Clinical Practice
Guidelines in Oncology Cervical cancer. V. 1.2009. http://www.nccn.org;
2009.
[7] Kirwan JM, Symonds P, Green JA, Tierney J, Collingwood M, and Williams CJ
(2003). A systematic review of acute and late toxicity of concomitant
chemoradiation for cervical cancer. Radiother Oncol 68, 217–226.
[8] Pearcey R, Brundage M, Drouin P, Jeffrey J, Johnston D, and Lukka H, et al
(2002). Phase III trial comparing radical radiotherapy with and without cisplatin
chemotherapy in patients with advanced squamous cell cancer of the cervix.
J Clin Oncol 20, 966–972.
[9] Chemoradiotherapy for Cervical Cancer Meta-Analysis Collaboration (2008).
Reducing uncertainties about the effects of chemoradiotherapy for
cervical cancer: a systematic review and meta-analysis of individual patient
data from 18 randomized trials. J Clin Oncol 26, 5802–5812. http:
//dx.doi.org/10.1200/JCO.2008.16.4368.
[10] van de Vijver MJ, He YD, van’t Veer LJ, Dai H, Hart AAM, and Voskuil DW, et al
(2002). A gene-expression signature as a predictor of survival in breast cancer.NEngl J
Med 347, 1999–2009. http://dx.doi.org/10.1056/NEJMoa021967.
[11] Yeoh E-J, Ross ME, Shurtleff SA, Williams WK, Patel D, and Mahfouz R, et al
(2002). Classification, subtype discovery, and prediction of outcome in pediatric
acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 1,
133–143.
[12] Barrier A, Boelle P-Y, Roser F, Gregg J, Tse C, and Brault D, et al (2006). Stage
II colon cancer prognosis prediction by tumor gene expression profiling. J Clin
Oncol 24, 4685–4691. http://dx.doi.org/10.1200/JCO.2005.05.0229.
[13] Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, and Rosenwald A, et al (2000).
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling.
Nature 403, 503–511. http://dx.doi.org/10.1038/35000501.
[14] Kittaneh M, Montero AJ, and Glück S (2013). Molecular profiling for
breast cancer: a comprehensive review. Biomark Cancer 5, 61–70. http:
//dx.doi.org/10.4137/BIC.S9455.[15] Hirschowitz L, NucciM, and Zaino RJ (2013). Problematic issues in the staging
of endometrial, cervical and vulval carcinomas. Histopathology 62, 176–202.
http://dx.doi.org/10.1111/his.12058.
[16] Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, and Ford R, et al
(2009). New response evaluation criteria in solid tumours: revised RECIST guideline
(version 1.1). Eur J Cancer 45, 228–247. http://dx.doi.org/10.1016/j.ejca.2008.10.026.
[17] Sotlar K, Diemer D, Dethleffs A, Hack Y, Stubner A, and Vollmer N, et al
(2004). Detection and typing of human papillomavirus by e6 nested multiplex
PCR. J Clin Microbiol 42, 3176–3184. http://dx.doi.org/10.1128/JCM.
42.7.3176-3184.2004.
[18] Simon A and Biot E (2010). ANAIS: analysis of NimbleGen arrays interface.
Bioinformatics 26, 2468–2469. http://dx.doi.org/10.1093/bioinformatics/btq410.
[19] Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, and Dudoit S, et al
(2004). Bioconductor: open software development for computational biology and
bioinformatics. Genome Biol 5, R80. http://dx.doi.org/10.1186/gb-2004-5-10-r80.
[20] van’t Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AAM, and Mao M, et al
(2002). Gene expression profiling predicts clinical outcome of breast cancer.
Nature 415, 530–536. http://dx.doi.org/10.1038/415530a.
[21] Roepman P, Wessels LFA, Kettelarij N, Kemmeren P, Miles AJ, and
Lijnzaad P, et al (2005). An expression profile for diagnosis of lymph node
metastases from primary head and neck squamous cell carcinomas. Nat
Genet 37, 182–186. http://dx.doi.org/10.1038/ng1502.
[22] Sturn A, Quackenbush J, and Trajanoski Z (2002). Genesis: cluster analysis of
microarray data. Bioinformatics 18, 207–208.
[23] Harima Y, Togashi A, Horikoshi K, Imamura M, Sougawa M, and Sawada S,
et al (2004). Prediction of outcome of advanced cervical cancer to
thermoradiotherapy according to expression profiles of 35 genes selected by
cDNA microarray analysis. Int J Radiat Oncol Biol Phys 60, 237–248. http:
//dx.doi.org/10.1016/j.ijrobp.2004.02.047.
[24] Kitahara O, Katagiri T, Tsunoda T, Harima Y, and Nakamura Y (2002).
Classification of sensitivity or resistance of cervical cancers to ionizing radiation
according to expression profiles of 62 genes selected by cDNA microarray
analysis. Neoplasia 4, 295–303. http://dx.doi.org/10.1038/sj.neo.7900251.
[25] RajkumarT,VijayalakshmiN, SabithaK, Shirley S, SelvaluxmyG, andBoseMV, et al
(2009). A 7 gene expression score predicts for radiation response in cancer cervix.BMC
Cancer 9, 365. http://dx.doi.org/10.1186/1471-2407-9-365.
[26] Wong YF, Selvanayagam ZE, Wei N, Porter J, Vittal R, and Hu R, et al (2003).
Expression genomics of cervical cancer: molecular classification and prediction of
radiotherapy response by DNA microarray. Clin Cancer Res 9, 5486–5492.
[27] Huang L, Zheng M, Zhou Q-M, Zhang M-Y, Jia W-H, and Yun J-P, et al
(2011). Identification of a gene-expression signature for predicting lymph node
metastasis in patients with early stage cervical carcinoma. Cancer 117,
3363–3373. http://dx.doi.org/10.1002/cncr.25870.
[28] Koch M and Wiese M (2013). Gene expression signatures of angiocidin and
darapladib treatment connect to therapy options in cervical cancer. J Cancer Res
Clin Oncol 139, 259–267. http://dx.doi.org/10.1007/s00432-012-1317-9.
[29] Bachtiary B, Boutros PC, Pintilie M, Shi W, Bastianutto C, and Li J-H, et al (2006).
Gene expression profiling in cervical cancer: an exploration of intratumor heterogeneity.
Clin Cancer Res 12, 5632–5640. http://dx.doi.org/10.1158/1078-0432.CCR-06-0357.
